| Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity E Duong, TB Fessenden, E Lutz, T Dinter, L Yim, S Blatt, A Bhutkar, ... Immunity 55 (2), 308-323. e9, 2022 | 245 | 2022 |
| Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy N Momin, NK Mehta, NR Bennett, L Ma, JR Palmeri, MM Chinn, EA Lutz, ... Science translational medicine 11 (498), eaaw2614, 2019 | 203 | 2019 |
| Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity Y Agarwal, LE Milling, JYH Chang, L Santollani, A Sheen, EA Lutz, ... Nature Biomedical Engineering 6 (2), 129-143, 2022 | 106 | 2022 |
| Maximizing response to intratumoral immunotherapy in mice by tuning local retention N Momin, JR Palmeri, EA Lutz, N Jailkhani, H Mak, A Tabet, MM Chinn, ... Nature Communications 13 (1), 109, 2022 | 66 | 2022 |
| Efficient identification of murine M2 macrophage peptide targeting ligands by phage display and next-generation sequencing GW Liu, BR Livesay, NA Kacherovsky, M Cieslewicz, E Lutz, A Waalkes, ... Bioconjugate chemistry 26 (8), 1811-1817, 2015 | 57 | 2015 |
| Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies EA Lutz, Y Agarwal, N Momin, SC Cowles, JR Palmeri, E Duong, V Hornet, ... Proceedings of the National Academy of Sciences 119 (36), e2205983119, 2022 | 26 | 2022 |
| Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies BM Lax, JR Palmeri, EA Lutz, A Sheen, JA Stinson, L Duhamel, ... Proceedings of the National Academy of Sciences 120 (31), e2300895120, 2023 | 18 | 2023 |
| Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice EA Lutz, N Jailkhani, N Momin, Y Huang, A Sheen, BH Kang, KD Wittrup, ... PNAS Nexus 1 (5), pgac244, 2022 | 16 | 2022 |
| An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy SC Cowles, A Sheen, L Santollani, EA Lutz, BM Lax, JR Palmeri, ... mAbs 14 (1), 2088454, 2022 | 8 | 2022 |
| CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs JR Palmeri, BM Lax, JM Peters, L Duhamel, JA Stinson, L Santollani, ... Nature Communications 15 (1), 1900, 2024 | 6 | 2024 |
| Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells NL Truex, A Rondon, SL Rössler, CC Hanna, Y Cho, BY Wang, ... ACS Central Science 9 (9), 1835-1845, 2023 | 4 | 2023 |
| Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy JR Palmeri, BM Lax, JM Peters, L Duhamel, JA Stinson, L Santollani, ... Biorxiv, 2023 | 2 | 2023 |
| 947 The activation states of tumor-resident type 2 dendritic cells impact the strength of ovarian cancer immune responses F Chatterjee, V Butty, EA Lutz, KD Wittrup, S Spranger Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1011 The signal strength of signal 2 and 3 during T cell priming affect the functional fate of an anti-tumor T cell response T Dinter, D Morgan, V Bhandarkar, L Pop, EA Lutz, KD Wittrup, JC Love, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applications RO Hynes, KD Wittrup, N Jailkhani, N Momin, E Lutz US Patent App. 18/162,512, 2023 | | 2023 |
| Engineering Intratumoral Cytokine Therapies for Cancer EA Lutz Massachusetts Institute of Technology, 2022 | | 2022 |
| 1023 The signal strength of signal 2 and 3 during T cell priming affect the functional fate of an anti-tumor T cell response D Morgan, V Bhandarkar, E Lutz, K Wittrup, S Spranger, T Dinter J Immunother 10 (2), A1-A1595, 2022 | | 2022 |
| 683 Type-I-interferon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immunity E Duong, T Fessenden, E Lutz, T Dinter, L Yim, S Blatt, A Bhutkar, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
